Combined PAR4 antagonism and factor Xa inhibition, therefore, has potential additive therapeutic efficacy that merits further clinical investigation to reduce arterial thrombosis and atherothrombotic events. This evidence concerns the gene F2RL3 and Venous thrombosis.